Abstract:Bcl-2 (B cell lymphoma-2) is an anti-apoptotic member of Bcl-2 family and its overexpression causes development of several types of cancer. The BH3 domain of pro-apoptotic and BH3-only proteins is capable of binding to Bcl-2 protein to induce apoptosis. This binding is the basis for the development of novel anticancer drug which would likely antagonize Bcl-2 overexpression. In this study we have identified BH3 domain of Bax (Bax BH3) as potentially the best Bcl-2 antagonist by performing docking of BH3 peptides (peptides representing BH3 domain of pro-apoptotic and BH3-only proteins) into the Bcl-2 hydrophobic groove formed by BH3, BH1 and BH2 domains (also referred as BH3 cleft). To predict the best small antagonist for Bcl-2, three groups of small peptides (pentapeptide, tetrapeptide and tripeptide) were designed and screened against Bcl-2 which revealed the structural importance of a set of residues playing a vital role in interaction with Bcl-2. The docking and scoring function identified KRIG and KRI as specific peptides among the screened small peptides responsible for Bcl-2 neutralization and would induce apoptosis. The applied pharmacokinetic and pharmacological filters to all small peptides signify that only IGD has drug-like properties and displayed good oral bioavailability. However, the obtained binding affinity of IGD to Bcl-2 was diminutive. Hence deprotonation, amidation, acetylation, benzoylation, benzylation, and addition of phenyl, deoxyglucose and glucose fragments were performed to increase the binding affinity and to prevent its rapid degradation. Benzoylated IGD tripeptide (IGD(bzo)) was observed to have increased binding affinity than IGD with acceptable pharmacokinetic filters. In addition, stability of Bcl-2/IGD(bzo) complex was validated by Molecular Dynamics (MD) simulations revealing improved binding energy, salt bridges and strong interaction energies. This study suggests a new molecule that inhibits Bcl-2 associated cancer/tumor regression.

Synthetic Peptide Sequence from the C-terminus of the Insulin-Like Growth Factor-I Receptor That Induces Apoptosis and Inhibition of Tumor Growth.

A Novel Class of Peptides That Induce Apoptosis and Abrogate Tumorigenesisin Vivo

Peptide screening to knockdown Bcl-2's anti-apoptotic activity: implications in cancer treatment

Cell Permeable Bcl-2 Binding Peptides: A Chemical Approach to Apoptosis Induction in Tumor Cells

An In-Tether Chiral Center Modulates the Proapoptotic Activity of the KLA Peptide.

Inhibition Of Insulin-Like Growth Factor-I Receptor (Igf-Ir) Signaling And Tumor Cell Growth By A Fully Human Neutralizing Anti-Igf-Ir Antibody

Design of peptidomimetics that inhibit the association of phosphatidylinositol 3-kinase with platelet-derived growth factor-beta receptor and possess cellular activity

Screening and Characterisation of a Novel Efficient Tumour Cell-Targeting Peptide Derived from Insulin-Like Growth Factor Binding Proteins

Apoptosis induced by (di-isopropyloxyphoryl-Trp) 2 -Lys-OCH 3 in K562 and HeLa cells

Functional evaluation of fluorescein-labeled derivatives of a peptide inhibitor of the EGF receptor dimerization

Synthetic Smac/DIABLO peptides enhance the effects of chemotherapeutic agents by binding XIAP and cIAP1 in situ

Structure-Based Discovery of an Organic Compound That Binds Bcl-2 Protein and Induces Apoptosis of Tumor Cells

Multiple Signaling Pathways of the Insulin-Like Growth Factor 1 Receptor in Protection from Apoptosis

Inhibition of Mitogen-Elicited Signal Transduction and Growth in Prostate Cancer with a Small Peptide Derived from the Functional Domain of DOC-2/DAB2 Delivered by a Unique Vehicle.

Recombinant Insulin-Like Growth Factor 1 Dimers: Receptor Binding Affinities and Activation Abilities

Silencing of the type 1 insulin-like growth factor receptor increases the sensitivity to apoptosis and inhibits invasion in human lung adenocarcinoma A549 cells

Insulin-like Growth Factor Factor Binding Protein-2 is a Novel Mediator of P53 Inhibition of Insulin-Like Growth Factor Signaling.

Comparative Study of the Potential Cell-Penetrating Peptide ∆M4 on Apoptosis Cell Signaling in A375 and A431 Cancer Cell Lines

Design, synthesis, biological activity and structural analysis of cyclic peptide inhibitors targeting the substrate recruitment site of cyclin-dependent kinase complexes

An Rgd-Modified Endostatin-Derived Synthetic Peptide Shows Antitumor Activity In Vivo

Selective Killing Of Transformed Cells By Cyclin/Cyclin-Dependent Kinase 2 Antagonists